NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

Johns Hopkins Medicine

Status and phase

Completed

Phase 2

Conditions

Bone Marrow Failure

Aplastic Anemia

Immunosuppression

Severe Aplastic Anemia

Treatments

Drug: Tacrolimus

Drug: Mycophenolate mofetil

Radiation: Total body irradiation

Drug: Fludarabine

Drug: Cyclophosphamide

Drug: Thymoglobulin

Study type

Interventional

Funder types

Other

Identifiers

NCT02833805

IRB00107139 (Other Identifier)

J1688

Details and patient eligibility

About

Our primary objective is to determine if it is feasible for previously untreated severe aplastic anemia (SAA) patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide.

Full description

This is a clinical trial of upfront bone marrow transplantation for patients with SAA who do not have a fully human leukocyte antigen (HLA) matched donor. The trial uses a conditioning regimen which has been successful in the refractory and relapsed setting to maximize engraftment and post transplant therapy to minimize graft versus host disease (GVHD). This would be used here in patients who have not yet undergone immunosuppressive therapy for their SAA or are thought to be unlikely to respond to immunosuppressive therapy for SAA.

Enrollment

21 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of inherited or acquired severe aplastic anemia (SAA)
One of the following available donors:
1. HLA-haploidentical relative
2. If recipient is >= 40 years old, may use HLA-matched related donor
3. For recipients with inherited bone marrow failure syndromes (IBMFS) with clear evidence of same disorder in potential related donors, may use 10/10 matched unrelated donor
Recipient and/or legal guardian must sign protocol informed consent
Donor must be willing to donate bone marrow
Left ventricular ejection fraction (LVEF) >= 40%. For recipients < 13 years old, shortening fraction >= 26% may be used instead.
Bilirubin < 3 x upper limit of normal (ULN) for age, unless patient has Gilbert's disease
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN for age
For patients >= 13 years old: estimated creatinine clearance > 50 mL/min using Cockcroft-Gault formula and actual body weight
For patients >= 1 but < 13 years old: glomerular filtration rate (GFR) estimated by updated Schwartz formula >= 90 mL/min/1.73 m^2. If estimated GFR is < 90 mL/min/1.73 m^2, 24-hour measured creatinine clearance must be > 50 mL/min/1.73 m^2.
For patients >= 8 years old, diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) > 40%; forced expiratory volume at one second (FEV1) > 50%; forced vital capacity (FVC) > 50%
For patients < 8 years old or unable to undergo pulmonary function testing: no evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation > 92% on room air
Karnofsky/Lansky status (depending on age) >= 70%
Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time. If unwilling, they must agree to complete abstinence.

Exclusion criteria

Previous administration of immunosuppressive therapy for SAA.
Fanconi anemia. At minimum, this diagnosis must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow in patients < 30 years old.
Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome (pre-MDS) or MDS on bone marrow examination
Presence of anti-donor antibodies
Prior allogeneic stem cell transplant
Prior solid organ transplant
Uncontrolled bacterial, viral, or fungal infection
HIV seropositivity
Active hepatitis B or C infection determined by serology and/or nucleic acid testing (NAT)
Pregnancy or active breastfeeding
Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent > 5 years previously. Other prior cancers will not be allowed unless approved by the PI.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

21 participants in 1 patient group

Bone marrow transplant

Experimental group

Description:

Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.